Neuro Lab · DeCure for X
DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for Huntington disease-like 1 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
No approved-drug candidate for huntington disease-like 1 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
prion protein (Kanno blood group) (PRNP) — PRNP is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
RCSB Protein Data Bank · entry 6LNI · 2.702 Å · ligand none (apo structure). Experimental structure, not a prediction.
Twenty-two patients with Huntington disease were followed for 13 to 40 months using a functional evaluation. Their functional capacities declined despite modest therapeutic effects from neuroleptic or antidepressant drugs. The quantitative scale used was considered applicable to long-term studies.
Huntington disease results from a polyglutamine repeat expansion near the N-terminal of the huntingtin protein. Genetic tests have been available for about 20 years, but current pharmacological treatments do not prevent or slow disease progression. Basic research has identified potential novel drug targets, but clear challenges remain in translating these discoveries into treatment strategies.
The disease is a rare autosomal dominant neurodegenerative condition that commonly presents in mid life with a movement disorder, psychiatric problems, and cognitive decline. The gene was identified in 1993, leading to major breakthroughs in understanding, but the disease remains incurable and fatal. Better characterisation of early clinical features has enabled new drug trials with the prospect of disease-modifying agents, and there is renewed impetus to treat symptoms and support patients and families.
What is still missing is a disease-modifying treatment that has been proven to slow or halt progression in patients, despite decades of genetic knowledge and basic research. The translation of identified drug targets into effective therapies remains an unsolved challenge, and no trial has yet delivered a drug that alters the fatal course of the disease.
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
AbstractTo assess the course of Huntington disease (HD) and the efficacy of therapy for chorea and depression, we used a functional evaluation for 22 HD patients who were followed for 13 to 40 months. Functional capacities of all patients declined notwithstanding the modest therapeutic effects of neuroleptic or antidepressant drugs. The quantitative scale seems applicable to long-term studies.
https://doi.org/10.1212/wnl.31.10.1333AbstractHuntington disease is a rare neurodegenerative disease resulting from insertion and/or expansion of a polyglutamine repeats close to the N-terminal of the huntingtin protein. Although unequivocal genetic tests have been available for about 20 years, current pharmacological treatments do not prevent or slow down disease progression. Recent basic research identified potential novel drug targets for the treatment of Huntington disease. However, there are clear challenges in translating these discoveries into treatment strategies for these patients. The following is a brief discussion of these challenges using our recent experience as an example.
https://doi.org/10.4161/rdis.28637AbstractAbstract Huntington’s disease (HD) is a rare autosomal dominant neurodegenerative condition that commonly presents in mid life with a combination of a movement disorder and psychiatric and cognitive problems. The identification of the gene underlying HD in 1993 has led to many major breakthroughs in our understanding of this disease, but it remains incurable and fatal to the present time. Our better understanding of the range of clinical features seen in this complex neuropsychiatric disorder and our ability to detect those earliest changes is leading to a new era of drugs trials for HD with the prospect of identifying disease-modifying agents. There is also a new impetus to look at drugs to better treat the symptoms and signs of HD as well as better support patients and their families in the community. In this chapter we outline some of these therapies, and provide clinical tips on how best to assess the HD patient.
https://doi.org/10.1093/brain/awh011Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
